
Sarissa’s SMARTChip is a purine biosensor which uses a finger-prick sample of blood to detect ischaemic brain events that occur during a stroke. ATP is the fuel used by all cells (including brain cells) to do work. In a healthy brain, cells continually regenerate ATP, but disruption of the blood supply (ischemia) prevents cells from getting nutrients. They can no longer regenerate ATP. Within seconds ATP breaks down into ‘purines’ which are released into the blood. Sarissa holds a number of patents on the technology
Product development for the advanced prototype SMARTChip system has been completed and the manufacturing process validated. The company will carry out a pivotal hospital-based clinical study to validate the biomarker in 2020. The study will then be expanded to include ambulance/paramedic use. Following completion of full product development, the company expects to obtain European and US regulatory clearance and launch products in 2023. Sarissa closed £1.2m investment in 2020 to continue trials and will be raising Series A funding of £5m in 2021.
2004 – £500k Wellcome Trust, Midven, Mercia
2009 – £270k DTI grant & Mercia 2014 – £400k i4i grant
2017 – £2m SBRI grant
2018 – £500k H2020 grant
2020 – £1.2m Mercia et al.
Chairman: Bill Moffitt
CEO: Dr John Clarkson
CTO: Prof. Nick Dale
NEDs: George Zajicek, Prof. Bruno Frenguelli
Contact: CEO john.clarkson@sarissa-biomedical.com Website: http://sarissa-diagnostics.com/
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
In oculis quidem se esse vult, summumque malum et, quantum.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.